DrugPatentWatch Database PreviewSee Plans and Pricing
« Back to Dashboard
Summary for Patent: 9,993,539
|Title:||Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers|
|Abstract:||A method of treating a patient who has liver cancer (HCC), breast cancer (BRCA), melanoma, and/or uterine cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, BRCA, melanoma, and/or uterine cancer.|
|Inventor(s):||Mahr; Andrea (Tubingen, DE), Weinschenk; Toni (Aichwald, DE), Schoor; Oliver (Tuebingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Houston, TX), Mueller; Phillip (Kassel, DE), Leibold; Julia (Tuebingen, DE), Goldfinger; Valentina (Tuebingen, DE)|
|Assignee:||IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)|
|Patent Claims:||1. A method of eliciting an immune response in a patient who has liver cancer (HCC), breast cancer (BRCA), melanoma, and/or uterine cancer, comprising administering to
said patient a composition comprising a population of activated T cells that selectively recognize the cancer cells that aberrantly express a peptide in the patient, wherein said peptide consists of the amino acid sequence of SMLGEEIQL (SEQ ID NO: 2),
wherein the activated T cells are cytotoxic T cells produced by contacting T cells with an antigen presenting cell that expresses the peptide in a complex with an MHC class I molecule on the surface of the antigen presenting cell, for a period of time
sufficient to activate said T cell specifically against the peptide.
2. The method of claim 1, wherein the T cells are autologous to the patient.
3. The method of claim 1, wherein the T cells are obtained from a healthy donor.
4. The method of claim 1, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells.
5. The method of claim 1, further comprising expanding T cells in vitro.
6. The method of claim 1, wherein the peptide is in a complex with an MHC molecule.
7. The method of claim 1, wherein the composition further comprises an adjuvant.
8. The method of claim 7, wherein the adjuvant is selected from the group consisting of imiquimod, resiguimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG oligonucleotides and derivatives, poly(I:C) and derivatives, RNA, sildenafil, and particulate formations with poly(lactid co-glycolid) (PLG) and virosomes.
9. The method of claim 1, wherein the antigen presenting cell is infected with a recombinant virus expressing the peptide.
10. The method of claim 9, wherein the antigen presenting cell is a dendritic cell or a macrophage.
11. The method of claim 1, further comprising stimulating the activated T cells in the presence of an anti-CD28 antibody and IL-12 to clonally expand the T cells.
12. The method of claim 1, wherein the population of activated T cells comprises CD8-positive cells.
13. The method of claim 1, wherein the contacting T cells with an antigen presenting cell is in vitro.
|Applicant||Tradename||Biologic Ingredient||Dosage Form||BLA||Number||Approval Date||Patent No.||Assignee||Estimated Patent Expiration||Status||Orphan||Source|
|Genentech||AVASTIN||bevacizumab||VIAL; INTRAVENOUS||125085||001||2004-02-26||See Pricing||IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)||2038-10-10||RX||search|
|Genentech||AVASTIN||bevacizumab||VIAL; INTRAVENOUS||125085||002||2004-02-26||See Pricing||IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)||2038-10-10||RX||search|
|>Applicant||>Tradename||>Biologic Ingredient||>Dosage Form||>BLA||>Number||>Approval Date||>Patent No.||>Assignee||>Estimated Patent Expiration||>Status||>Orphan||>Source|
|Country||Patent Number||Publication Date|
|World Intellectual Property Organization (WIPO)||2017021527||Apr 27, 2017|
|World Intellectual Property Organization (WIPO)||2017021527||Feb 09, 2017|
|United States of America||10155032||Dec 18, 2018|
|United States of America||10238727||Mar 26, 2019|
|United States of America||2017037089||Feb 09, 2017|
|United States of America||2017305982||Oct 26, 2017|
|United States of America||2017326215||Nov 16, 2017|
|>Country||>Patent Number||>Publication Date|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.